“Finishing the primary three affected person injections of Eyecyte-RPE™ represents a essential milestone for our quest to discover a remedy for Dry AMD. With the assist of exceptionally expert surgeons at our trial websites, we’re optimistic of translating our analysis for societal profit,” Battu stated in an announcement.
In a joint assertion, Dr Rajpal Vohra (AIIMS, Delhi) , Dr Raja Narayanan (LV Prasad Eye Institute, Hyderabad), Dr Rushikesh Naigonkar (Ganpati Netralaya, Jalna), and Dr Rohan Chawla (AIIMS, Delhi), retinal surgeons concerned within the research, stated “Dry AMD and related imaginative and prescient loss current an enormous burden on sufferers in India and overseas. We’re enthusiastic about supporting this analysis which has the potential of serving to such sufferers. It’s a matter of nice satisfaction that such an innovation is popping out of India for the world and hope that that is the beginning of a brand new age of drugs the place India leads the way in which.”
Dr Ramesh Byrapaneni, Managing Director, Endiya Companions stated, “As a clinician and an early investor in Eyestem, I’m thrilled to see Eyestem taking their first product developed from induced pluripotent stem cells into medical improvement. It’s a defining second for any drug discovery firm to maneuver the product from the preclinical research into human medical trials and I personally look ahead to them disrupting the cell remedy ecosystem globally and setting benchmarks in high quality, innovation, and accessibility on this sector.”
Since 2017, Bengaluru-based Eyestem has developed a scalable cell remedy platform for incurable ailments and is shifting its flagship product for Dry AMD into human trials.